AD/PD 2022 | Which plasma biomarkers hold the most promise in Alzheimer’s Disease?

Charlotte Teunissen • 17 Mar 2022

AD/PD 2022

A wide range of plasma biomarkers are currently in development for Alzheimer’s disease, reflecting different aspects of disease pathology including amyloid plaque formation, neurodegeneration, and astrocyte activation. With numerous options on the horizon, the question is raised regarding which plasma biomarker holds the most promise. Charlotte Teunissen, PhD, VU University Medical Center Amsterdam, Amsterdam, The Netherlands, discusses the unique aspects of several putative markers and their aptitude for diagnosis and prognostication, emphasizing the importance of analyzing multiple biomarkers to get a more complete picture of an individual’s diagnosis. This interview took place at the AD/PD™ 2022 Conference in Barcelona, Spain.

Disclosures

Grants: Research of CET is supported by the European Commission (Marie Curie International Training Network, grant agreement No 860197 (MIRIADE), Innovative Medicines Initiatives 3TR (Horizon 2020, grant no 831434) and JPND (bPRIDE), National MS Society (Progressive MS alliance) and Health Holland, the Dutch Research Council (ZonMW), Alzheimer Drug Discovery Foundation, The Selfridges Group Foundation, Alzheimer Netherlands, Alzheimer Association. CT is recipient of ABOARD, which is a public-private partnership receiving funding from ZonMW (#73305095007) and Health~Holland, Topsector Life Sciences & Health (PPP-allowance; #LSHM20106). ABOARD also receives funding from Edwin Bouw Fonds and Gieskes-Strijbisfonds. CET has a collaboration contract with ADx Neurosciences, Quanterix and Eli Lilly, performed contract research or received grants from AC-Immune, Axon Neurosciences, Bioconnect, Biogen, Bioorchstra, Brainstorm Therapeutics, Celgene, EIP Pharma, Eisai, Novo Nordisk, PeopleBio, Roche, Toyama, Vivoryon. She serves on editorial boards of Medidact Neurologie/Springer, Alzheimer Research and Therapy, Neurology: Neuroimmunology & Neuroinflammation, and is editor of a Neuromethods book Springer.
Speaker contract: Roche